Search

Pomalidomide prolongs survival in refractory myeloma patients

MM-003 is a large, multi-centre phase 3 study that assessed the efficacy and safety of a new drug, Pomalidomide (POM) in combination with low-dose dexamethasone (POM+LoDex) and compared this combination with high dose dexamethasone in MM patients with late stage…

Read more

Does the patient with myelofibrosis feel better through Pacritinib?

Pacritinib is an oral next-generation multikinase inhibitor with specificity for JAK2 and FLT3 being evaluated to treat myelofibrosis in two Phase 3 trials.

Read more

Daratumumab Shows Remarkable Benefit in Relapsed or Refractory Multiple Myeloma in the POLLUX Study

Daratumumab is a fully human monoclonal antibody that binds to a novel target on myeloma cells.

Read more

SWG Committee

Current committee members
Konstanze Döhner, Germany (Chair (EHA Board member))
Dominique Bonnet, France (Vice-Chair)
Immacolata Andolfo, Italy
Igor Aurer, Croatia
Raul Cordoba, Spain
Hermann Einsele, Germany
Eleni Gavriilaki, Greece (Representative, Young EHA Committee)
Kirsten Gronbaek, Denmark (EHA Board)
Esther Oliva, Italy
Marc Raaijmakers, The Netherlands
Josef Vormoor, The Netherlands
Aim
The SWG Committee…

Read more

The HARMONY project: learning to work in BIG (DATA) teams

The HARMONY project: learning to work in BIG (DATA) teams

By Anna Kabanova PhD, YoungEHA committee member

On 26 and 27 September 2019 several YoungEHA members, including myself, had the chance to participate in the 4th General Assembly of the HARMONY Alliance…

Read more

Highlights from the SWG

The following activities, which were organized by EMN, also constitute contributions to and participation in the work of the EHA SWG on Multiple Myeloma.

Read more